Black Diamond Therapeutics is a clinical-stage oncology company developing MasterKey therapies—small-molecule inhibitors designed to target families of oncogenic mutations that drive cancer while sparing normal proteins—with the goal of overcoming treatment resistance and achieving brain penetration for central nervous system disease. The company's lead candidate, silevertinib, is a fourth-generation EGFR inhibitor being developed for non-small cell lung cancer and glioblastoma, while its pipeline includes RAF and FGFR2/3 selective inhibitors. Black Diamond plans to generate revenue through direct U.S. commercialization of its owned programs, out-licensing deals such as its partnership with Servier Pharmaceuticals, and strategic partnerships to advance its pipeline.